These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10537436)

  • 21. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
    Russo G; McPake B
    Health Policy Plan; 2010 Jan; 25(1):70-84. PubMed ID: 19843636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative approaches to pharmaceutical price regulation in the European Union.
    Mrazek MF
    Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. If it ain't broke, don't price fix it: the OFT and the PPRS.
    Towse A
    Health Econ; 2007 Jul; 16(7):653-65. PubMed ID: 17595047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug prices: how they are established and existing price control systems.
    Rovira Forns J
    Salud Colect; 2015 Mar; 11(1):35-48. PubMed ID: 25853829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing Reimbursement Drug Price Risk to Enhance R&D Incentives without Raising Drug Prices/Expenditures: Implications of Simulations Based on Questionnaire Survey of Pharmaceutical Companies in Japan.
    Nakamura H; Wakutsu N
    Health Policy; 2020 Jul; 124(7):714-720. PubMed ID: 32475740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Price and utilisation differences for statins between four countries.
    Thai LP; Vitry AI; Moss JR
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):71-81. PubMed ID: 28800399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pricing policy towards the sourcing of cheaper drugs in Cyprus.
    Merkur S; Mossialos E
    Health Policy; 2007 May; 81(2-3):368-75. PubMed ID: 16949176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995-2007.
    Puig-Junoy J; López-Valcárcel BG
    Health Policy; 2014 Jun; 116(2-3):170-81. PubMed ID: 24641938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.
    Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG
    Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas.
    Ward DJ; Doos L; Stevens A
    BMJ Open; 2019 May; 9(5):e027625. PubMed ID: 31061053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug price reform in the UK: debunking the myths.
    Thornton S
    Health Econ; 2007 Oct; 16(10):981-92. PubMed ID: 17853505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector.
    Hostenkamp G
    Health Policy; 2013 Jun; 111(1):68-77. PubMed ID: 23587548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.